Expanding the presence of AstraZeneca in the Asia-Pacific region in general and China specifically is a priority for AstraZeneca, according to John Ramsey, AstraZeneca’s Vice President for Global Development. Ramsey stressed that AstraZeneca is interested in developing drugs that address the needs of China’s population. Toward that end, AstraZeneca has established its Innovation Center China (ICC), which began operations in 2007 and establishes relationships with China’s universities and medical centers. More details...

Stock Symbol: (NYSE: AZN)